TY - JOUR JO - Archives of Medical Science SN - 1734-1922 VL - 14 IS - 3 PY - 2018 ID - Tłustochowicz2018 TI - Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009–2014 AB - Approximately 1% of the population suffers from rheumatoid arthritis (RA) worldwide (0.45% in Poland). The therapy consists of the use of disease-modifying antirheumatic drugs (DMARDs). Biologics are used in the form of the drug programme. Analysis of the NHF database demonstrated the sequence of conversion between drugs and time spent in a single treatment. In 2009, the patients would start the following treatments: adalimumab 5.8%; etanercept 14.4%; infliximab 23.1%; leflunomide 53.6%; rituximab 3%. After the first year 16% of patients changed therapy or abstained, and in the second year this situation affected 65% of patients. The following percentages maintained the same treatment in the last 6 years: infliximab 4%; adalimumab 15%; etanercept 21%; leflunomide on prescription was continued by 70%. Patients remain too long on the same therapy when it is inefficient. Achieving remission or low disease activity (DAS28 < 2.6) should take place within 6 months of starting therapy. AU - Tłustochowicz, Małgorzata AU - Śliwczyński, Andrzej M. AU - Brzozowska, Melania AU - Teter, Zbigniew AU - Marczak, Michał SP - 569 EP - 571 DA - 2018 DO - 10.5114/aoms.2016.58924 UR - http://dx.doi.org/10.5114/aoms.2016.58924 ER -